As the majority of BRG1-deficient tumors are negative for mutations in other genes that can be targeted by existing therapies40, it would be advantageous to exploit DDR deficiencies in SWI/SNF cancers therapeutically. This evidence concerns the gene SMARCA4 and cancer.